Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback